
Triveni Bio
- Active openings
- 2
- US-based roles
- 2
- Remote-friendly
- 0
- Last updated
- 2026-08-22
What Triveni Bio is hiring for
Open positions
2 activeAbout Triveni Bio
Claim to unlockMission, culture, and benefits - visible once this page is claimed and verified.
Updates
Triveni Bio Raises $65 Million Series C Financing to Expand Scope of First-in-Class Bispecific TRIV-573 Clinical Studies and Drive Next-Stage Company Growth
Triveni Bio Doses First Healthy Volunteers with Next-Generation Bispecific Antibody TRIV-573 Targeting Kallikreins 5 & 7 and Interleukin 13 in Phase 1 Clinical Trial
Triveni Doses First Subject in Global Phase 2 Proof of Concept Study of TRIV-509 in Atopic Dermatitis, Presents Translational Data at 2025 EADV Congress Demonstrating Novel Biology in Patient Samples
Fierce Biotech names Triveni Bio a “Fierce 15” Biotech Company of 2025
Triveni Bio Doses First Healthy Volunteers in Clinical Trial for TRIV-509, Coinciding with Preclinical Data Presentations Further Validating Novel Kallikrein 5/7 Biology in Atopic Dermatitis